This federal contract award, with the ID 36F79724D0185|36C24525N0364, was issued by the U.S. Department of Veterans Affairs (VA) to the prime contractor Amicus Therapeutics US, LLC. The contract is a delivery order for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., has an existing Federal Supply Schedule (FSS) contract (36F79724D0185) with the VA under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, valued at $13,024,630 and valid through August 31, 2029. The current delivery order has a ceiling value of $21,891.21 and an ultimate completion date of February 11, 2025. This contract award was not set aside for any specific business type. Amicus Therapeutics US, LLC has consistently supplied the VA's regional Veterans Integrated Service Networks (VISNs) with the Galafold drug to support the healthcare needs of veterans.
Generated 2/7/25, 9:12 AM